IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) have been given a consensus recommendation of “Moderate Buy” by the sixteen research firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and fourteen have issued a buy rating on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $46.00.

IDYA has been the subject of several recent research reports. Guggenheim started coverage on shares of IDEAYA Biosciences in a report on Thursday, September 18th. They set a “buy” rating and a $50.00 target price for the company. Barclays began coverage on IDEAYA Biosciences in a research report on Thursday, September 4th. They set an “overweight” rating and a $40.00 price objective for the company. Mizuho boosted their target price on IDEAYA Biosciences from $44.00 to $46.00 and gave the stock an “outperform” rating in a report on Tuesday, November 11th. Stephens restated an “overweight” rating and set a $45.00 price target on shares of IDEAYA Biosciences in a report on Tuesday, September 9th. Finally, New Street Research set a $30.00 price target on IDEAYA Biosciences in a research report on Tuesday, October 21st.

IDEAYA Biosciences Trading Up 0.2%

Shares of IDYA stock opened at $34.57 on Friday. The company’s fifty day moving average price is $33.48 and its 200-day moving average price is $27.64. The stock has a market cap of $3.03 billion, a PE ratio of -18.59 and a beta of 0.05. IDEAYA Biosciences has a 12 month low of $13.45 and a 12 month high of $37.08.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $1.33 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $1.45. The business had revenue of $207.83 million for the quarter, compared to analysts’ expectations of $59.98 million. On average, sell-side analysts forecast that IDEAYA Biosciences will post -3.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Arizona State Retirement System grew its holdings in shares of IDEAYA Biosciences by 1.5% during the third quarter. Arizona State Retirement System now owns 23,324 shares of the company’s stock valued at $635,000 after buying an additional 353 shares during the last quarter. Daiwa Securities Group Inc. lifted its position in IDEAYA Biosciences by 16.1% in the 2nd quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock valued at $66,000 after acquiring an additional 436 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in IDEAYA Biosciences by 16.1% in the 3rd quarter. PNC Financial Services Group Inc. now owns 3,881 shares of the company’s stock valued at $106,000 after acquiring an additional 537 shares in the last quarter. CWM LLC boosted its stake in IDEAYA Biosciences by 33.0% during the 2nd quarter. CWM LLC now owns 3,153 shares of the company’s stock valued at $66,000 after purchasing an additional 782 shares during the last quarter. Finally, E Fund Management Co. Ltd. increased its holdings in shares of IDEAYA Biosciences by 7.8% in the 2nd quarter. E Fund Management Co. Ltd. now owns 12,225 shares of the company’s stock worth $257,000 after purchasing an additional 881 shares in the last quarter. Institutional investors own 98.29% of the company’s stock.

About IDEAYA Biosciences

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.